US-based medical technology firm Medtronic received clearance by the Federal Trade Commission this week to merge with Ireland-based Covidien, a deal that will see Medtronic relocate its tax bracket abroad for lower rates.
According to reports, Medtronic has been cleared to buy Covidien for $42.9 billion. Medtronic, however, will have to divest its drug-coated balloon catheter operations to appease competition concerns, reports say.
The deal was first announced last June and will boost Medtronic’s standing in the global medical technology industry to compete more closely with industry leader Johnson & Johnson. The deal must also secure approval by regulators in China and the EU, reports say; Canada cleared the plans Wednesday.
Full content: The Independent
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI